Compounds > buphedrone
Page last updated: 2024-11-13

buphedrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

buphedrone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53249194
CHEMBL ID3298875
MeSH IDM0573994

Synonyms (18)

Synonym
chembl3298875 ,
bdbm50023180
AKOS015950992
unii-vd73947m0o
vd73947m0o ,
mabp
alpha-methylamino-butyrophenone
buphedrone
2-(methylamino)-1-phenylbutan-1-one
408332-79-6
J2.929.921H ,
DDPMGIMJSRUULN-UHFFFAOYSA-N
.alpha.-methylamino-butyrophenone
2-(methylamino)-1-phenyl-1-butanone
1-butanone, 2-(methylamino)-1-phenyl-
alpha-methylaminobutyrophenone
Q4998026
DTXSID701014170

Research Excerpts

Overview

Buphedrone is a stimulant that is snorted, smoked or taken orally.

ExcerptReferenceRelevance
"Buphedrone is a stimulant that is snorted, smoked or taken orally."( Detection of buphedrone in biological and non-biological material--two case reports.
Adamowicz, P; Byrska, B; Zuba, D, 2013)		1.48

Treatment

ExcerptReferenceRelevance
"Treatment with buphedrone supported CPP and self-administration, enhanced locomotor activity and produced behavioral sensitization when mice were challenged with methamphetamine."( The new designer drug buphedrone produces rewarding properties via dopamine D1 receptor activation.
Hong, SI; Hwang, JY; Jang, CG; Kim, HC; Lee, SY; Ma, SX; Oh, JH; Seo, JY, 2018)		1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1224714Inhibition of NET-mediated norepinephrine uptake in rat synaptosomes2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224718Agonist activity at human 5HT2C expressed in HEK293 cells at 10 uM by calcium mobilization assay2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224711Induction of DAT-mediated dopamine release in rat synaptosomes2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224712Inhibition of SERT-mediated serotonin uptake in rat synaptosomes2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224717Agonist activity at human 5HT2B expressed in HEK293 cells at 10 uM by calcium mobilization assay2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224720Agonist activity at human 5HT2A expressed in CHOK1 cells at 10 uM after 3 hrs by beta-arrestin recruitment assay2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224715Induction of NET-mediated norepinephrine release in rat synaptosomes2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224716Agonist activity at human 5HT2A expressed in HEK293 cells at 10 uM by calcium mobilization assay2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
AID1224719Agonist activity at human 5HT1A expressed in CHO cells coexpressing Galpha16 at 10 uM by calcium mobilization assay2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (62.50)24.3611
2020's3 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.84 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3,4-methylenedioxyamphetamine
3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.		2.3110benzodioxoles
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		2.1710amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
cathinone
cathinone: alkaloid from khat shrub, Catha edulis; RN given refers to parent cpd without isomeric designation. cathinone : The S stereoisomer of 2-aminopropiophenone.		7.69202-aminopropiophenone;
monoamine alkaloid		central nervous system stimulant;
psychotropic drug
4-methoxymethcathinone
4-methoxymethcathinone: structure in first source		2.110
raclopride
Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.		2.1710salicylamides
sch 23390
SCH 23390: a selective D1-receptor antagonist. SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.		2.1710benzazepine
4-methylethcathinone
4-methylethcathinone: structure in first source		2.110aromatic ketone
3,4-dimethylmethcathinone
3,4-dimethylmethcathinone: a designer drug; structure in first source		2.3110aromatic ketone
3-fluoromethcathinone
3-fluoromethcathinone: structure in first source		2.110
2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one
2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one: Hallucinogen		2.3110butanone
pentedrone
pentedrone: structure in first source		7.4920
pentylone
pentylone: structure in first source		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Liver Injury, Drug-Induced
[description not available]		02.3110
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.3110